NO972732D0 - Karsinombehandling - Google Patents

Karsinombehandling

Info

Publication number
NO972732D0
NO972732D0 NO972732A NO972732A NO972732D0 NO 972732 D0 NO972732 D0 NO 972732D0 NO 972732 A NO972732 A NO 972732A NO 972732 A NO972732 A NO 972732A NO 972732 D0 NO972732 D0 NO 972732D0
Authority
NO
Norway
Prior art keywords
karsinombehandling
carcinomas
inducer
prevention
conjunction
Prior art date
Application number
NO972732A
Other languages
English (en)
Other versions
NO972732L (no
NO318587B1 (no
Inventor
Lawrence Sterling Young
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of NO972732L publication Critical patent/NO972732L/no
Publication of NO972732D0 publication Critical patent/NO972732D0/no
Publication of NO318587B1 publication Critical patent/NO318587B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
NO19972732A 1994-12-13 1997-06-13 Anvendelse av en CD40-reseptorbinder for fremstilling av et medikament for forebyggelse av epitelcelleproliferasjon eller for behandling av karsinomer i epitelcellesystemer, samt for forsterkning av mottakeligheten til neoplastiske epitelceller for anti-neoplastisk medikamentindusert apotose NO318587B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425060.2A GB9425060D0 (en) 1994-12-13 1994-12-13 Carcinoma treatment
PCT/GB1995/002807 WO1996018413A1 (en) 1994-12-13 1995-12-01 Carcinoma treatment

Publications (3)

Publication Number Publication Date
NO972732L NO972732L (no) 1997-06-13
NO972732D0 true NO972732D0 (no) 1997-06-13
NO318587B1 NO318587B1 (no) 2005-04-11

Family

ID=10765814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19972732A NO318587B1 (no) 1994-12-13 1997-06-13 Anvendelse av en CD40-reseptorbinder for fremstilling av et medikament for forebyggelse av epitelcelleproliferasjon eller for behandling av karsinomer i epitelcellesystemer, samt for forsterkning av mottakeligheten til neoplastiske epitelceller for anti-neoplastisk medikamentindusert apotose

Country Status (12)

Country Link
EP (1) EP0806963B1 (no)
JP (1) JP4076230B2 (no)
AT (1) ATE203676T1 (no)
AU (1) AU691996B2 (no)
CA (1) CA2207779C (no)
DE (1) DE69522012T2 (no)
FI (1) FI118918B (no)
GB (1) GB9425060D0 (no)
MX (1) MX9704372A (no)
NO (1) NO318587B1 (no)
NZ (1) NZ296161A (no)
WO (1) WO1996018413A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ278740A (en) * 1993-12-23 1998-05-27 Immunex Corp Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
KR101023367B1 (ko) 1998-08-11 2011-03-18 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7138379B2 (en) 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
PL1680141T3 (pl) * 2003-11-04 2011-04-29 Novartis Vaccines & Diagnostics Inc Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
CA2609269C (en) 2005-05-26 2014-08-05 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
KR20080073725A (ko) 2005-11-01 2008-08-11 노파르티스 아게 항-ｃｄ40 항체의 용도
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
BRPI0619579B8 (pt) 2005-12-09 2022-01-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Métodos para aumentar a expectativa de vida replicativa e/ou estabilidade de uma célula produtora de anticorpo, para expressar um gene de uma célula b codificando a cadeia pesada de ig e/ou cadeia leve de ig, para produzir linhagem de células b, para obter anticorpos, e, método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
US8945564B2 (en) 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
CN101910414B (zh) 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
CA2758523C (en) 2009-04-18 2019-03-12 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
DK2646466T3 (en) 2010-12-02 2017-06-06 Aimm Therapeutics Bv METHODS AND METHODS FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
EP3099709B1 (en) 2014-01-31 2019-12-25 AIMM Therapeutics B.V. Means and methods for producing stable antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
JPH10510526A (ja) 1998-10-13
DE69522012T2 (de) 2002-04-25
EP0806963B1 (en) 2001-08-01
CA2207779A1 (en) 1996-06-20
AU3988495A (en) 1996-07-03
WO1996018413A1 (en) 1996-06-20
NO972732L (no) 1997-06-13
JP4076230B2 (ja) 2008-04-16
NZ296161A (en) 2001-10-26
GB9425060D0 (en) 1995-02-08
AU691996B2 (en) 1998-05-28
EP0806963A1 (en) 1997-11-19
MX9704372A (es) 1998-02-28
CA2207779C (en) 2009-10-06
DE69522012D1 (de) 2001-09-06
NO318587B1 (no) 2005-04-11
FI972484L (fi) 1997-06-12
FI118918B (fi) 2008-05-15
FI972484A0 (fi) 1997-06-12
ATE203676T1 (de) 2001-08-15

Similar Documents

Publication Publication Date Title
NO972732L (no) Karsinombehandling
DK0877734T3 (da) Quinolin- og quinazolinforbindelser, der er egnede i terapi
TR200000726T2 (tr) Budesonid ve formoterol'ün yeni kullanımı.
DE69115182D1 (de) Polymerzusammensetzung und ihre Verwendung.
ATE209366T1 (de) Elektrochrome oder photoelektrochrome vorrichtung
DE69519303T8 (de) Dünner, saugfähiger Artikel mit Dochtwirkungs- und Druck-Festigungseigenschaften
DE69109847D1 (de) LI, MG und AL-METHID-SALZE UND DARAUS HERGESTELLTE ELEKTROLYTE FÜR BATTERIEN.
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
ES292314U (es) Un articulo sanitario
DE59008501D1 (de) Neue, stickstoffhaltige Titanocene und deren Verwendung.
NO912625L (no) Betongstein belagt med kopolymerfilm, samt fremgangsmaate for fremstilling av betongsteinen.
TW355847B (en) A surface treatment steel plate used for battery case, batterycase and battery using the case
DE3766276D1 (de) Gegen abblaettern bestaendige polymerzusammensetzung, sowie beschichtung.
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
NO902532D0 (no) Fremgangsmaate for fremstilling av flytebro, samt flytebrofortrinnsvis fremstillet i henhold til fremgangsmaaten.
AU646439B2 (en) Novel retinoids
DE69109052D1 (de) Polyolefin-Zusammensetzung und deren Verwendung.
DE59004277D1 (de) Copolymerisat sowie dessen Verwendung.
FI88228C (fi) Dielektrisk resonatorkonstruktion
MX9700813A (es) Nuevos derivados 3-substituidos de 3h-2,3-benzodiazepina, su preparacion y su uso como medicamentos.
ZA972776B (en) 4-[(thien-2-yl)methyl]-imidazole analgesics
DE69108396D1 (de) Hohe kolloidale Kapazitätsekundärbatterie, Kolloidelektrolyt und dessen Verwendung, sowie deren Herstellungsverfahren.
ES2135296A1 (es) Puerta de vidrio estructural autoportante.
DK505184D0 (da) Pladeprofildrager med hvaelvet, tvaerprofileret overgjord
DE59106847D1 (de) Überzugsmittel sowie dessen Verwendung.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees